文献速递妇科

卵巢间变性癌:单中心经验与分子分析

Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
PubMed 文献 · Gynecol Oncol · 2025-03-19

该研究回顾性分析了2013至2023年间一家三级转诊中心收治的13例卵巢间变性癌,多数起源于黏液性癌,常见KRAS、TP53和CDKN2A改变,铂耐药率高,亟需新型治疗策略。

要点

  • 13例卵巢间变性癌中12例(92%)与黏液性癌相关或起源于黏液性癌。
  • 10例测序中8例(80%)存在KRAS G12D/V热点突变,TP53和CDKN2A改变各6例(60%)。
  • 6例进展或复发者中5例为铂耐药,全部患者中位总生存28.1个月。

核心结论

  • 卵巢间变性癌以KRAS、TP53和CDKN2A改变为特征,因铂耐药率高,需要新型治疗方法。

研究设计与样本

  • 回顾性研究,从机构数据库识别2013至2023年间卵巢间变性癌病例,共13例。

主要发现

  • 13例肿瘤中12例(92%)与黏液性癌相关或起源于黏液性癌,6例(46%)位于壁结节。
  • 诊断时中位年龄39岁(范围19-77),6例I期(其中3例IA期)、1例II期、5例III期、1例IV期。
  • 术后一线治疗包括卡铂-紫杉醇双药(8例)、5-氟尿嘧啶-奥沙利铂为基础方案(FOLFOX 1例;XELOX 2例)和异环磷酰胺/紫杉醇(1例),2例早期患者未接受辅助化疗。
  • 6例进展或复发,其中5例铂耐药,1例初始无进展间期为6.8个月;无复发的7例中位随访79.7个月。
  • 全部患者中位总生存28.1个月(范围7.8-139.2),5例死于该病;10例测序中KRAS G12D/V突变8例(80%),TP53改变6例(60%),CDKN2A改变6例(60%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We describe a tertiary referral center's experience with anaplastic ovarian carcinoma and characterize the genetic landscape of these rare tumors. METHODS: Anaplastic ovarian carcinomas were retrospectively identified from institutional databases from 2013 to 2023. Clinical data and survival outcomes were abstracted from the electronic medical record. Molecular data were obtained from clinical tumor-normal panel sequencing. RESULTS: Thirteen tumors were identified; 12 (92 %) were associated with or arose from a mucinous carcinoma, and 6 (46 %) were found in a mural nodule. Median age at diagnosis was 39 years (range, 19-77); 6 patients had stage I disease (3 stage IA), 1 had stage II, 5 had stage III, and 1 had stage IV. All patients underwent surgery. First-line postoperative therapy included carboplatin-paclitaxel doublet (n = 8), a 5-fluorouracil-oxaliplatin-based regimen (FOLFOX, n = 1; XELOX, n = 2), and ifosfamide/paclitaxel (n = 1). Two patients did not receive adjuvant chemotherapy for early-stage disease. Six patients had progression or recurrence; 5 had platinum-refractory disease and 1 had an initial progression-free interval of 6.8 months. For the 7 patients without recurrence, median follow-up was 79.7 months. Median overall survival for all patients was 28.1 months (range, 7.8-139.2). Five patients died of their disease. Ten patients had clinical panel sequencing, revealing recurrent somatic KRAS G12D/V hotspot mutations (8 of 10, 80 %) and genetic alterations affecting cell cycle-related genes, including TP53 (6 of 10, 60 %) and CDKN2A (6 of 10, 60 %). CONCLUSIONS: Anaplastic ovarian carcinoma is characterized by KRAS, TP53, and CDKN2A alterations. Novel treatment approaches are needed due to the high rate of platinum-refractory disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sullivan MW, Chui MH, Selenica P, et al. Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis. Gynecol Oncol. 2025. PMID: 40112666. doi:10.1016/j.ygyno.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。